<DOC>
	<DOC>NCT00380367</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India. Quadrivalent HPV Vaccine is composed of L1 virus-like particles (VLPs) from HPV types 6, 11, 16, and 18.</brief_summary>
	<brief_title>Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Females Age 9 To 15 Years Females Not Sexually Active And Not Plan On Becoming Sexually Active During The Study No Fevers 24 Hours Prior To The First Injection Participant Had Received A Prior Vaccination With A HPV Vaccine Participant Has Allergies To Vaccine Component Including Aluminum And Yeast Participant Has (Human Immunodeficiency Virus) HIV Infection Participant Is Immunocompromised Participant Received Or Plans To Receive BloodDerived Product Within 6 Months Prior To The First Injection Participant Received Or Plans To Receive Immune Globulin Preparation Within 6 Months To The First Injection</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>